SecBot SecBot
SC 13G ·Filed Oct 30, 2026

ANRO

Alto Neuroscience, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed2d 10h ago SEC0002100119-26-001537
Passive investor 5%+ stake
Actionable Insight • Neutral

Vanguard's passive 5%+ stake is routine for a large index fund manager and does not signal activist intent. Monitor for any subsequent 13D conversion or additional accumulation by Vanguard or other institutional holders, though none is expected given the passive certification.

DirectionNeutral
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

Executive Summary

Vanguard Capital Management LLC disclosed a 5.02% passive stake in Alto Neuroscience via a new Schedule 13G filing, reporting beneficial ownership of 1,970,108 common shares as of September 30, 2026. This is a new 13G filing for Vanguard, which was not listed as a filer in prior passive stake filings by other investors. The filing certifies passive intent and is consistent with Vanguard's typical index fund and managed account strategies.

Key Financial Metrics

Stake
5.02%
Investor
Vanguard Capital Management LLC
Investor Type
mutual fund

Key Facts

  • Vanguard Capital Management LLC filed a new Schedule 13G disclosing a 5.02% stake in Alto Neuroscience Inc.
  • Beneficial ownership: 1,970,108 shares of common stock as of September 30, 2026.
  • The filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control.
  • Vanguard was not a filer in prior SC 13G/A filings for Alto Neuroscience (Perceptive Advisors, Sirenia Capital, EcoR1 Capital).
  • The stake is held across Vanguard affiliates including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd.

Financial Impact

5.02% stake valued at approximately $46M based on $916M market cap at analysis time.

ownership concentration

Risk Factors

  • No material risks identified from this passive stake filing.
  • Vanguard's stake is below the 10% threshold that would typically warrant closer scrutiny.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0002100119-26-001537
Document: 0002100119-26-001537-index.html0002100119-26-001537
Document: 0002100119-26-001537.txt0002100119-26-001537
13 reports for ANRO
Performance horizon
83% Hit rate @ T+5 5 of 6 directional calls Went positive at some point 6 of 6 best @ T+60▲ +66.79%Jun 11, 2026
Filters
Rows
Reports for ANRO, sortable and filterable
TypeNow
Oct 30, 2026
2d ago
SC 13G
NEUTRAL ★ 3/10
$23.00awaiting T+5awaiting T+5$22.60 (−1.74%)
Aug 12, 2026
11w ago
Institutional Cluster
BULLISH ★ 6/10
$32.30 $34.25▲ +6.04%▲ +8.00%$22.60 (−30.03%)
Jul 14, 2026
15w ago
8-K
BEARISH ★ 6/10
$27.80 $25.90▲ +6.83%▲ +5.54%$22.60 (+18.71%)
Jul 14, 2026
15w ago
424B5
BEARISH ★ 6/10
$27.80 $25.90▲ +6.83%▲ +5.54%$22.60 (+18.71%)
Jul 13, 2026
15w ago
8-K
BULLISH ★ 6/10
$28.03 $27.54▼ −1.75%▼ −0.96%$22.60 (−19.37%)
Jun 11, 2026
20w ago
Institutional Cluster
BULLISH ★ 7/10
$21.47 $22.74▲ +5.92%▲ +5.24%$22.60 (+5.26%)
May 29, 2026
22w ago
3
NEUTRAL ★ 2/10
$19.80 $18.26▼ −7.78%▼ −5.03%$22.60 (+14.14%)
May 28, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$20.22 $18.85▼ −6.78%▼ −6.73%$22.60 (+11.77%)
May 13, 2026
24w ago
8-K
MIXED ★ 6/10
$22.85 $20.45▼ −10.50%▼ −9.35%$22.60 (−1.09%)
Apr 21, 2026
27w ago
EFFECT
NEUTRAL ★ 3/10
$25.59 $24.47▼ −4.38%▼ −5.46%$22.60 (−11.68%)
Showing 10 of 13

US Market Status

Market Closed · Opens Tue (13h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026